Resumen: Biomarkers are useful tools to help in disease diagnosis and follow-up. According to the US Food & Drug Administration, biomarkers are defined as measurable elements that can be used as indicators in normal biological and pathological processes, or in response to an exposure or therapeutic interventions. Molecular, histologic, radiographic or physiological characteristics are some of those biomarkers (www.fda.gov). The term biomarker is currently being applied to molecular markers that define a specific biological status (1). Considering these factors, the “ideal” biomarker should fulfill susceptibility/risk, be reliable, and can be used for diagnosis, monitoring, prognosis, prediction and pharmacodynamic response.
Some useful biomarkers such as the number of BCR/ABL transcripts in chronic myeloid leukemia serve as sensitive indicators that help in the monitoring of the molecular response, a quantitative instrument to monitor the long-term molecular response to therapy (2) or for example the serum concentration of M-component in monoclonal gammopathies ... Idioma: Inglés DOI: 10.21037/atm.2018.10.69 Año: 2018 Publicado en: ANNALS OF TRANSLATIONAL MEDICINE 6 (2018), S81 [6 pp] ISSN: 2305-5839 Factor impacto JCR: 3.689 (2018) Categ. JCR: ONCOLOGY rank: 79 / 229 = 0.345 (2018) - Q2 - T2 Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTAL rank: 45 / 135 = 0.333 (2018) - Q2 - T2 Factor impacto SCIMAGO: 0.958 - Medicine (miscellaneous) (Q1)